Proteostasis Therapeutics, Inc. announced that On December 5, 2017, Brett Hagen, VP, Finance and Principal Accounting Officer provided notice of his resignation from the company, effective December 31, 2017, for personal reasons. On December 7, 2017, the Board of Directors of the company elected Helen M. Boudreau, the company’s Chief Financial Officer and Treasurer, as the company’s Principal Accounting Officer. Ms. Boudreau has been Chief Financial Officer and Treasurer since July 2017. Ms. Boudreau served on company Board of Directors from February 2016 to July 2017. Prior to joining the company, Ms. Boudreau served as the Chief Financial Officer of FORMA Therapeutics, Inc. from 2014 to 2017.